CAMBRIDGE, Mass.--(BUSINESS WIRE)--Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, announced today that it will receive a $1 million milestone payment from its collaborator Nuvelo, Inc. The milestone payment has been triggered by Nuvelo’s enrollment of the first volunteer in a Phase 1 study of NU172, a thrombin-inhibiting aptamer. The Phase 1 study is being conducted at a single center with approximately 30 healthy male volunteers and is designed to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172.
